Novo Nordisk A S 6-K, filed Nov 5, 2026
Novo Nordisk A S (NVO)
About this 6-K
Novo Nordisk A S filed this 6-K on November 5, 2026.
Novo Nordisk A/S disclosed that Executive Vice President, R&D and Chief Scientific Officer Martin Holst Lange sold 12,000 shares at DKK 285.00 on 20 26-11-04, totaling DKK 3,420 ,000 .0 0. AI summary
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 5, 2026
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark. 5 November 2026 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney to publish the transactions on their behalf ..
Please find below a statement of such trading in shares issued by Novo Nordisk.
Page 2 of 3
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Martin Holst Lange | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive Vice President, R&D and Chief Scientific Officer (CSO) | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) |
Description of the financial instrument, type of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0062498333 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 285.00 | 12,000 | ||||
| d) |
Aggregated information · Aggregated volume · Price |
12,000 DKK 3,420 ,000 .0 0 | |||
| e) | Date of the transaction | 20 26-11-04 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
Page 3 of 3
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 66,500 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo -B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram , LinkedIn, TikTok, Facebook , X and YouTube.
Contacts for further information
| Novo Media: | |
|
Ambre James -Brown +45 3079 9289 globalmedia@novonordisk.com |
Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com |
| Novo Investors: | |
|
Michael Novod +45 3075 6050 nvno@novonordisk.com |
Sina Meyer +45 3079 6656 azey@novonordisk.com |
|
Max Ung +45 3077 6414 mxun@novonordisk.com |
Christoffer Togo Solgaard -Tullin +45 3079 1471 cftu@novonordisk.com |
|
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com |
Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com |
|
Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com |
Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 66 / 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: November 5, 2026 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |